Charles H. Pippitt

486 total citations
14 papers, 356 citations indexed

About

Charles H. Pippitt is a scholar working on Reproductive Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Charles H. Pippitt has authored 14 papers receiving a total of 356 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Reproductive Medicine, 6 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Charles H. Pippitt's work include Ovarian cancer diagnosis and treatment (10 papers), Angiogenesis and VEGF in Cancer (4 papers) and Intraperitoneal and Appendiceal Malignancies (3 papers). Charles H. Pippitt is often cited by papers focused on Ovarian cancer diagnosis and treatment (10 papers), Angiogenesis and VEGF in Cancer (4 papers) and Intraperitoneal and Appendiceal Malignancies (3 papers). Charles H. Pippitt collaborates with scholars based in United States, Belgium and Australia. Charles H. Pippitt's co-authors include Ignace Vergote, Raj Nagarkar, Allan Covens, Marjan Tassoudji, Amit M. Oza, Prafull Ghatage, Setsuko K. Chambers, Diane Provencher, Howard D. Homesley and Hoa Nguyen and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Obstetrics and Gynecology and Gynecologic Oncology.

In The Last Decade

Charles H. Pippitt

14 papers receiving 344 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Charles H. Pippitt United States 8 155 154 139 70 57 14 356
Lisbeth Haugom Norway 13 192 1.2× 103 0.7× 75 0.5× 52 0.7× 206 3.6× 19 486
Gert Jan Fleuren Netherlands 13 111 0.7× 51 0.3× 116 0.8× 56 0.8× 74 1.3× 16 464
Kyriaki Pliarchopoulou Greece 10 141 0.9× 58 0.4× 160 1.2× 38 0.5× 90 1.6× 14 351
M. Combe France 11 76 0.5× 197 1.3× 249 1.8× 69 1.0× 83 1.5× 22 477
Kanae Nosaka Japan 12 178 1.1× 33 0.2× 153 1.1× 48 0.7× 135 2.4× 36 425
R Bellino Italy 9 80 0.5× 62 0.4× 98 0.7× 65 0.9× 24 0.4× 24 382
Małgorzata Babińska Poland 12 133 0.9× 35 0.2× 94 0.7× 77 1.1× 233 4.1× 20 394
Danuta Skomra Poland 12 112 0.7× 36 0.2× 115 0.8× 72 1.0× 71 1.2× 45 344
A P Kudelka United States 13 184 1.2× 176 1.1× 169 1.2× 36 0.5× 79 1.4× 24 598
Evan Rosenbaum United States 12 62 0.4× 33 0.2× 258 1.9× 62 0.9× 194 3.4× 34 419

Countries citing papers authored by Charles H. Pippitt

Since Specialization
Citations

This map shows the geographic impact of Charles H. Pippitt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles H. Pippitt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles H. Pippitt more than expected).

Fields of papers citing papers by Charles H. Pippitt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles H. Pippitt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles H. Pippitt. The network helps show where Charles H. Pippitt may publish in the future.

Co-authorship network of co-authors of Charles H. Pippitt

This figure shows the co-authorship network connecting the top 25 collaborators of Charles H. Pippitt. A scholar is included among the top collaborators of Charles H. Pippitt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles H. Pippitt. Charles H. Pippitt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Vergote, Ignace, Russell J. Schilder, Charles H. Pippitt, et al.. (2014). A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. Gynecologic Oncology. 135(1). 25–33. 15 indexed citations
2.
Vergote, Ignace, Agustin A. García, John P. Micha, et al.. (2013). Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer. Journal of Clinical Oncology. 31(32). 4060–4066. 34 indexed citations
3.
Wong, Shirley, Sumitra Ananda, Ignace Vergote, et al.. (2012). A PHASE 1B STUDY OF TREBANANIB (AMG 386) IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) OR TOPOTECAN (T) IN WOMEN WITH RECURRENT OVARIAN CANCER. Asia-Pacific Journal of Clinical Oncology. 8. 316–317. 1 indexed citations
4.
Karlan, Beth Y., Amit M. Oza, Gary Richardson, et al.. (2011). Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer. Journal of Clinical Oncology. 30(4). 362–371. 171 indexed citations
5.
García, Agustin A., Ignace Vergote, John P. Micha, et al.. (2011). The role of NKTR-102 in women with platinum resistant/refractory ovarian cancer and failure on pegylated liposomal doxorubicin (PLD).. Journal of Clinical Oncology. 29(15_suppl). 5047–5047. 4 indexed citations
6.
Leach, Joseph W., Sidney Scudder, Charles H. Pippitt, et al.. (2010). Phase Ib study of AMG 386 combined with either pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with advanced ovarian cancer.. Journal of Clinical Oncology. 28(15_suppl). 5049–5049. 5 indexed citations
7.
Vergote, Ignace, John P. Micha, Charles H. Pippitt, et al.. (2010). Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer.. Journal of Clinical Oncology. 28(15_suppl). 5013–5013. 17 indexed citations
8.
Colombo, N., E. Kutarska, Charles H. Pippitt, et al.. (2009). Phase II study comparing volociximab (an antiangiogenic antibody) and pegylated liposomal doxorubicin (PLD) with PLD alone in recurrent ovarian or primary peritoneal cancer. Journal of Clinical Oncology. 27(15_suppl). 5560–5560. 17 indexed citations
9.
Gordon, Alan N., Lina Asmar, Mark Messing, et al.. (2004). Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer. Gynecologic Oncology. 94(2). 533–539. 7 indexed citations
10.
Morgan, Mark A., et al.. (1989). Vaginal and Bladder Angiosarcoma After Therapeutic Irradiation. Southern Medical Journal. 82(11). 1434–1436. 30 indexed citations
11.
Pippitt, Charles H., Joanna M. Cain, Thomas B. Hakes, Virginia K. Pierce, & John L. Lewis. (1988). Primary chemotherapy and the role of second-look laparotomy in non-dysgerminomatous germ cell malignancies of the ovary. Gynecologic Oncology. 31(2). 268–275. 13 indexed citations
12.
Smith, Jeffrey J., et al.. (1987). Automated quantitative fluorescent image analysis of cervical cytology. Gynecologic Oncology. 28(3). 241–254. 4 indexed citations
13.
Hatjis, Christos G., James C. Rose, Charles H. Pippitt, & Melissa Swain. (1985). Effect of treatment with sodium valproate on plasma adrenocorticotropic hormone and cortisol concentrations in pregnancy. American Journal of Obstetrics and Gynecology. 152(3). 315–316. 1 indexed citations
14.
Pippitt, Charles H., et al.. (1981). Cisplatin-associated cortical blindness. Gynecologic Oncology. 12(2). 253–255. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lisbeth Haugom Breakdown of academic impact, for papers by Gert Jan Fleuren Breakdown of academic impact, for papers by Kyriaki Pliarchopoulou Breakdown of academic impact, for papers by M. Combe Breakdown of academic impact, for papers by Kanae Nosaka Breakdown of academic impact, for papers by R Bellino Breakdown of academic impact, for papers by Małgorzata Babińska Breakdown of academic impact, for papers by Danuta Skomra Breakdown of academic impact, for papers by A P Kudelka Breakdown of academic impact, for papers by Evan Rosenbaum
Rankless by CCL
2026